1. Search Result
Search Result
Results for "

wild-type p97/VCP ATPase

" in MedChemExpress (MCE) Product Catalog:

1341

Inhibitors & Agonists

1

Screening Libraries

18

Fluorescent Dyes

16

Biochemical Assay Reagents

51

Peptides

2

MCE Kits

16

Inhibitory Antibodies

129

Natural
Products

28

Recombinant Proteins

78

Isotope-Labeled Compounds

39

Antibodies

10

Click Chemistry

25

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12861
    CB-5083
    45+ Cited Publications

    p97 Cancer
    CB-5083 is a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase/VCP. CB-5083 selectively inhibits p97 through its D2 site with the IC50 of 11 nM .
    CB-5083
  • HY-110078
    Eeyarestatin I
    10+ Cited Publications

    p97 Apoptosis Cancer
    Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I inhibits Sec61 translocon. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I interferes at a step prior to proteasomal degradation. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects .
    Eeyarestatin I
  • HY-15713
    NMS-873
    15+ Cited Publications

    p97 Cancer
    NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC50 value of 30 nM.
    NMS-873
  • HY-14588
    Lopinavir
    15+ Cited Publications

    ABT-378

    HIV HIV Protease SARS-CoV Infection Neurological Disease Cancer
    Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 14.2 μM .
    Lopinavir
  • HY-128870

    Drug-Linker Conjugates for ADC Cancer
    Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates .
    Mal-PEG2-VCP-Eribulin
  • HY-15945
    DBeQ
    5+ Cited Publications

    JRF 12

    p97 Autophagy Apoptosis Cancer
    DBeQ is a selective, potent, reversible, and ATP-competitive p97 inhibitor, with an IC50 value of 1.5 μM and 1.6 μM for p97(wt) and p97(C522A), respectively; DBeQ also inhibits Vps4 with an IC50 of 11.5 μM.
    DBeQ
  • HY-123872
    MSC1094308
    1 Publications Verification

    p97 Cancer
    MSC1094308 is a non-competitive and reversible VPS4B/p97 (VCP) (I/II type AAA ATPase) allosteric inhibitor, with IC50 values of 0.71 μM and 7.2 μM for VPS4B and p97, respectively . MSC1094308 inhibits the D2 ATPase activity by binding to a agentable hotspot of p97. MSC1094308 can be used in study of cancer .
    MSC1094308
  • HY-164718

    BAY 2927088

    EGFR Cancer
    Sevabertinib (BAY 2927088) is an orally active and reversible dual EGFR-HER2 inhibitor (IC 50 <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer .
    Sevabertinib
  • HY-19795
    ML240
    5 Publications Verification

    p97 Cancer
    ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML240
  • HY-128724
    CB-5339
    2 Publications Verification

    p97 Cancer
    CB-5339 is an oral activity potent p97 inhibitor with an IC50 <30 nM. CB-5339 can be used for leukemia research . CB-5339 extracted from WO2015109285A1 compound FF07.
    CB-5339
  • HY-123636

    p97 Cancer
    UPCDC-30245 is an allosteric p97 inhibitor with an IC50 of approximately 27 nM . UPCDC-30245 inhibits the p97 mutant N660K similar to wild type (WT; IC50=300 nM) and shows 3-fold resistance for p97 mutant T688A . UPCDC-30245 can be used in the research of cancer .
    UPCDC-30245
  • HY-19797A

    p97 Cancer
    ML241 hydrochloride is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML241 hydrochloride
  • HY-130084

    ADC Linker Cancer
    Mal-PEG2-VCP-NB is a claevable ADC linker containing a Maleimide group, 2-unit PEG and a VCP NB.
    Mal-PEG2-VCP-NB
  • HY-15714
    NMS-859
    1 Publications Verification

    p97 Cancer
    NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC50s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
    NMS-859
  • HY-108917
    Morphothiadin
    5+ Cited Publications

    GLS4

    HBV Infection
    Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir (HY-B1826)-resistant HBV with an IC50 of 12 nM.
    Morphothiadin
  • HY-137342

    PROTACs Src IRAK Bcr-Abl MAP4K Cyclin G-associated Kinase (GAK) CDK Cancer
    SB1-G-187 is a multi-target kinase PROTAC degrader with activity against various kinases including GCK, YES1, IRAK1 and LYN. SB1-G-187 induces degradation of target kinases via a p97-dependent pathway, and forms ternary complexes with CRBN and specific functional kinases. SB1-G-187 can be used in tumor-related research. (Pink: multi-target kinase ligand (HY-125142); Blue: CRBN ligand (HY-A0003); Black: linker) .
    SB1-G-187
  • HY-138233

    p97 Neurological Disease Inflammation/Immunology
    KUS121, a valosin-containing protein (VCP, p97) modulator with significant neuroprotective effects, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress .
    KUS121
  • HY-157508
    VCP Activator 1
    2 Publications Verification

    p97 Others
    VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .
    VCP Activator 1
  • HY-16271
    Kevetrin hydrochloride
    4 Publications Verification

    4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride

    MDM-2/p53 Apoptosis Cancer
    Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .
    Kevetrin hydrochloride
  • HY-139606

    p97 Cancer
    VCP/p97 inhibitor-1 is a potent inhibitor of VCP/p97 (also called Cdc48, CDC-. 48, or Ter94) with an IC50 of 54.7 nM. VCP/p97 inhibitor-1 causes the dysregulation of protein homeostasis and disturbs the degradation of misfolded polypeptides by the ubiquitin-proteasome system (UPS) .
    VCP/p97 inhibitor-1
  • HY-11067
    WHI-P97
    1 Publications Verification

    JAK Inflammation/Immunology
    WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .
    WHI-P97
  • HY-W111581
    Copper(II) diethyldithiocarbamate
    1 Publications Verification

    Diethyldithiocarbamic acid copper salt

    Apoptosis Caspase Cancer
    Copper(II) diethyldithiocarbamate (Diethyldithiocarbamic acid copper salt) is a Copper(II) and diethyldithiocarbamate coordination polymer. Copper(II) diethyldithiocarbamate binds tightly to NPL4 and induces its aggregation, disrupting the p97-NPL4-UFD1 pathway. Copper(II) diethyldithiocarbamate causes ubiquitinated proteins accumulation and impairs waste proteins degradation, thus resulting in cell apoptosis. Copper(II) diethyldithiocarbamate inhibits tumor growth in MDA-MB-231 xenograft mice models. Copper(II) diethyldithiocarbamate can be used for the research of cancer, such as breast cancer .
    Copper(II) diethyldithiocarbamate
  • HY-128888

    Isocitrate Dehydrogenase (IDH) Cancer
    (R,R)-GSK321 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM. (R,R)-GSK321 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity .
    (R,R)-GSK321
  • HY-18936
    Alda-1
    15+ Cited Publications

    Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    Alda-1 is a potent and selective ALDH2 agonist, which activates wild-type ALDH2 and restores near wild-type activity to ALDH2*2.
    Alda-1
  • HY-115282A
    JNJ-63576253
    1 Publications Verification

    TRC-253

    Androgen Receptor Cancer
    JNJ-63576253 (TRC-253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the research of castration-resistant prostate cancer (CRPC) .
    JNJ-63576253
  • HY-172762

    HDAC Molecular Glues Histone Demethylase Cancer
    S234984 is a molecular glue degrader. S234984 forms a stable ternary complex with wild-type KBTBD4 E3 ligase and HDAC2 to drive neomorphic ubiquitination and degradation of CoREST1 and LSD1. S234984 can be used for the research of medulloblastoma .
    S234984
  • HY-168324

    p97 Others
    UP158 enhances the activity of ATPase, and activates valosin-containing protein (VCP) with an EC50 of 2.57 μM .
    UP158
  • HY-124776

    p97 Cancer
    NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration. NPD8733 specifically binds to valosin-containing protein (VCP)/p97, a member of the ATPase-associated with diverse cellular activities (AAA+) protein family. NPD8733 has the potential for the research of cancer diseases .
    NPD8733
  • HY-168325

    p97 Others
    UP12 is an ATPase activity activator that activates the ATPase activity of valosin-containing protein (VCP), with an EC50 of 1.24 μM. UP12 is applicable to research related to multisystem proteinopathies .
    UP12
  • HY-146074

    Proton Pump Cancer
    RUVBL1/2 ATPase-IN-1 (compound 18) is a potent and selective inhibitor of RUVBL1/2 ATPase with IC50 values of 6.0 and 7.7 μM, respectively. RUVBL1 and RUVBL2 are highly conserved AAA ATPases (ATPases Associated with various cellular Activities) and highly relevant to the progression of cancer. RUVBL1/2 ATPase-IN-1 has the potential for the research of cancer diseases .
    RUVBL1/2 ATPase-IN-1
  • HY-136450

    TCBZ-SO

    Parasite BCRP Infection Cancer
    Triclabendazole sulfoxide (TCBZ-SO) is an orally active ABCG2 inhibitor with antiparasitic activity. Triclabendazole sulfoxide inhibits ABCG2-mediated active efflux and ATPase activity. Triclabendazole sulfoxide increases the intracellular accumulation of Mitoxantrone (HY-13502). Triclabendazole sulfoxide reduces the apical-directed transepithelial transport of Nitrofurantoin and Danofloxacin, while increasing their basolateral-directed transepithelial transport. Triclabendazole sulfoxide elevates the plasma levels of sulfasalazine in wild-type mice. Triclabendazole sulfoxide decreases ABCG2-mediated secretion of Nitrofurantoin into milk in wild-type lactating mice. Triclabendazole sulfoxide can be used in the research of insecticidal agents and cancers such as breast cancer .
    Triclabendazole sulfoxide
  • HY-141715

    Antibiotic Infection
    BRD-8000.3, as a specific EfpA inhibitor, is a narrow-spectrum, bactericidal antimycobacterial agent with good wild-type activity. BRD-8000.3 can be used for the research of tuberculosis .
    BRD-8000.3
  • HY-19797

    p97 Cancer
    ML241 is a potent, selective and competitive p97 ATPase inhibitor with an IC50 of 0.11 μM. ML241 can be used for the research of cancer .
    ML241
  • HY-174984

    p97 Caspase p62 Cancer
    VCP/p97 IN-3 is a VCP/p97 allosteric inhibitor. VCP/p97 IN-3 shows the inhibitory activity against the VCP proteins with an IC50 of 9 nM and the mutant VCP proteins with IC50 of 12 nM (N660K) and 19 nM (V474A/D649A). VCP/p97 IN-3 increases K48-linked ubiquitination and the level of cleaved caspase-3. VCP/p97 IN-3 activates ER-stress and the UPR. VCP/p97 IN-3 inhibits tumor growth in RPMI-8226 cell subcutaneous xenograft mouse models. VCP/p97 IN-3 can be used for the study of multiple myeloma .
    VCP/p97 IN-3
  • HY-148122

    p97 Cancer
    NW 1028 is a potent VCP/p97 inhibitor. NW 1028 targets the ND1L domain of p97 and inhibits the degradation of a p97-dependent reporter. NW 1028 has good binding affinity with Kd values of 100 and 285 nM for ND1L and full length p97, respectively. NW 1028 has the function of regulating the mitotic spindle of cells .
    NW 1028
  • HY-158415

    ATP Synthase EHD Protein Cancer
    ATPase-IN-4 (Compound MS1) inhibits the ATPase activity of EHD4 (IC50: 0.92 μM). ATPase-IN-4 also inhibits EHD2 enzymatic activity
    ATPase-IN-4
  • HY-77113

    Raf Cancer
    B-Raf IN 11 is a B-Raf V600E mutant kinase inhibitor with an IC50 of 76 nM, and exhibits an IC50 of 238 nM against wild-type B-Raf kinase. B-Raf IN 11 inhibits the kinase activities of B-Raf V600E mutant and wild-type B-Raf kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .
    B-Raf IN 11
  • HY-RS15621

    Small Interfering RNA (siRNA) Others

    VCP Human Pre-designed siRNA Set A contains three designed siRNAs for VCP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    VCP Human Pre-designed siRNA Set A
    VCP Human Pre-designed siRNA Set A
  • HY-12083

    Bcr-Abl Cancer
    PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba?F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .
    PPY-A
  • HY-162735

    GPR65 Inflammation/Immunology
    BRD5080 is a GPR65 agonist. BRD5080 activates GPR65 to enhance the cAMP signaling pathway, reduce the expression of inflammatory cytokines and chemokines in dendritic cells, enhance the activity of human wild-type, mouse wild-type, and human GPR65 I231L variant receptors in a pH-dependent manner, and mediate the recruitment of Gαs protein. BRD5080 can be used in the research of inflammatory bowel disease .
    BRD5080
  • HY-174847

    p97 Cancer
    VCP/p97 IN-2 (Compound V13) is a VCP/p97 inhibitor with IC50 of 32 nM for p97. VCP/p97 IN-2 has excellent antitumor activities and significantly inhibits tumor growth in Molm-13 xenograft mice model. VCP/p97 IN-2 can be used for acute myeloid leukemia (AML) research .
    VCP/p97 IN-2
  • HY-148041

    ATP Synthase Others
    ATPase-IN-2 is an ATPase inhibitor with an IC50 value of 0.9 μM. ATPase-IN-2 inhibits C. difficile toxin B (TcdB) glycohydrolase activity with an AC50 value of 30.91 μM. ATPase-IN-2 can be used for the research of ATP-related .
    ATPase-IN-2
  • HY-177650

    ALN-TTRsc04

    Transthyretin (TTR) Others
    Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.
    Nucresiran
  • HY-179257

    p97 Cancer
    p97-IN-2 (Compound 14) is a p97 ATPase (IC50 = 0.6 μM) inhibitor. p97-IN-2 can inhibit cell proliferation, such as HCT15 (IC50 = 1.1 μM) and SW403 (IC50 = 0.8 μM) cells. p97-IN-2 can be used for cancer research .
    p97-IN-2
  • HY-128871

    Drug-Linker Conjugates for ADC Cancer
    VCP-Eribulin is a bioactive molecule-linker conjugate designed for ADCs (Drug-Linker Conjugates for ADC), formed by conjugating an ADC linker (VCP) with Eribulin (HY-13442). Eribulin is a unique microtubule inhibitor exhibiting antitumor activity. VCP-Eribulin can be utilized for antibody conjugation .
    VCP-Eribulin
  • HY-162935

    Proton Pump Others
    V-ATPase-IN-1 (Compound 3b-03) is a Vacuolar-type H +-ATPases (V-ATPase) inhibitor (IC50 = 194.80 μM) that can effectively target the V-ATPase subunit A (Kd = 0.803 μM). V-ATPase-IN-1 exhibits insecticidal activity against M. separata (LC50 = 2.64 mM) and contributes to research in the development of chemical insecticides .
    V-ATPase-IN-1
  • HY-174844

    p97 Cancer
    p97-IN-1 is an orally active p97 inhibitor (IC50 = 26 nM). p97-IN-1 can significantly inhibit the proliferation of tumor cells. p97-IN-1 can be used for research on acute myeloid leukemia (AML) .
    p97-IN-1
  • HY-118460

    VCP/p97-IN-PPA

    p97 Cancer
    ACJI-99C (VCP/p97-IN-PPA) is a selective covalent p97/VCP ATPase inhibitor with an IC50 value of 0.6 μM. ACJI-99C binds with p97 active site residues to block ATPase activity. ACJI-99C irreversibly blocks degradation of p97-dependent protein in cells. ACJI-99C inhibits proliferation of cancer cells, including p97 inhibitor-resistant lines. ACJI-99C can be used for the research of colorectal cancer .
    ACJI-99C
  • HY-168005

    p97 ATP Synthase Cancer
    NSC799462 is a triazole inhibitor of p97 ATPase. NSC799462 inhibits p97 ATPase activity (IC50 = 15 nM) by binding to a specific site on p97 and causing local changes in the p97 structure .
    NSC799462
  • HY-19795R

    p97 Cancer
    ML240 (Standard) is the analytical standard of ML240. This product is intended for research and analytical applications. ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC50 value of 100 nM.
    ML240 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: